A humanoid robot works on a factory line, showcasing advanced automation in real-world production. PHOTO: AGIBOT
Robots that learn on the job: AgiBot tests reinforcement learning in real-world manufacturing.
Updated
November 27, 2025 3:26 PM
A humanoid robot works on a factory line, showcasing advanced automation in real-world production. PHOTO: AGIBOT
Shanghai-based robotics firm AgiBot has taken a major step toward bringing artificial intelligence into real manufacturing. The company announced that its Real-World Reinforcement Learning (RW-RL) system has been successfully deployed on a pilot production line run in partnership with Longcheer Technology. It marks one of the first real applications of reinforcement learning in industrial robotics.
The project represents a key shift in factory automation. For years, precision manufacturing has relied on rigid setups: robots that need custom fixtures, intricate programming and long calibration cycles. Even newer systems combining vision and force control often struggle with slow deployment and complex maintenance. AgiBot’s system aims to change that by letting robots learn and adapt on the job, reducing the need for extensive tuning or manual reconfiguration.
The RW-RL setup allows a robot to pick up new tasks within minutes rather than weeks. Once trained, the system can automatically adjust to variations, such as changes in part placement or size tolerance, maintaining steady performance throughout long operations. When production lines switch models or products, only minor hardware tweaks are needed. This flexibility could significantly cut downtime and setup costs in industries where rapid product turnover is common.
The system’s main strengths lie in faster deployment, high adaptability and easier reconfiguration. In practice, robots can be retrained quickly for new tasks without needing new fixtures or tools — a long-standing obstacle in consumer electronics production. The platform also works reliably across different factory layouts, showing potential for broader use in complex or varied manufacturing environments.
Beyond its technical claims, the milestone demonstrates a deeper convergence between algorithmic intelligence and mechanical motion.Instead of being tested only in the lab, AgiBot’s system was tried in real factory settings, showing it can perform reliably outside research conditions.
This progress builds on years of reinforcement learning research, which has gradually pushed AI toward greater stability and real-world usability. AgiBot’s Chief Scientist Dr. Jianlan Luo and his team have been at the forefront of that effort, refining algorithms capable of reliable performance on physical machines. Their work now underpins a production-ready platform that blends adaptive learning with precision motion control — turning what was once a research goal into a working industrial solution.
Looking forward, the two companies plan to extend the approach to other manufacturing areas, including consumer electronics and automotive components. They also aim to develop modular robot systems that can integrate smoothly with existing production setups.
Keep Reading
A new bet on early heart failure detection and why women’s health is at the center.
Updated
December 23, 2025 12:36 PM
A doctor holding an artificial heart model. PHOTO: ADOBE STOCK
Heart disease does not always announce itself clearly, especially in women. Many of the symptoms are ordinary, including fatigue, shortness of breath and swelling. These signs are frequently dismissed or explained away. As a result, many women are diagnosed late, when treatment options are narrower and outcomes are worse. That diagnostic gap is the context behind a recent investment involving Ultromics and the American Heart Association’s Go Red for Women Venture Fund.
Ultromics is a health technology company that uses artificial intelligence to help doctors spot early signs of heart failure from routine heart scans. It has received a strategic investment from the American Heart Association’s Go Red for Women Venture Fund.
The focus of the investment is a long-standing blind spot in cardiac care. Heart failure with preserved ejection fraction, or HFpEF, affects millions of people worldwide, with women disproportionately impacted. It is one of the most common forms of heart failure, yet also one of the hardest to diagnose. Studies even show women are twice as likely as men to develop the condition and around 64% of cases go undiagnosed in routine clinical practice.
Ultromics works with a tool most patients already experience during heart care: the echocardiogram. There is no new scan and no added burden for patients. Its software analyzes standard heart ultrasound images and looks for subtle patterns that point to early heart failure. The goal is clarity. Give clinicians better signals earlier, before the disease advances.
“Heart failure with preserved ejection fraction is one of the most complex and overlooked diseases in cardiology. For too long, clinicians have been expected to diagnose it using tools that weren't built to detect it and as a result, many patients are identified too late,” said Ross Upton, PhD, CEO and Founder of Ultromics. “By augmenting physicians' decision making with EchoGo, we can help them recognize disease at an earlier stage and treat it more effectively.”
The stakes are high. Research suggests women are twice as likely as men to develop the condition and that a majority of cases are missed in routine clinical practice. That delay matters. New therapies can reduce hospitalizations and improve survival, but only if patients are diagnosed in time.
This is why early detection has become a priority for mission-driven investors. “Closing the diagnostic gap by recognizing disease before irreversible damage occurs is critical to improving health for women—and everyone,” said Tracy Warren, Senior Managing Director, Go Red for Women Venture Fund. “We are gratified to see technologies, such as this one, that are accepted by leading institutions as advances in the field of cardiovascular diagnostics. That's the kind of progress our fund was created to accelerate.”
Ultromics’ platform is already cleared by regulators for clinical use and is being deployed in hospitals across the US and UK. The company says its technology has analyzed hundreds of thousands of heart scans, helping clinicians reach clearer conclusions when traditional methods fall short.
Taken together, the investment reflects a broader shift in healthcare. Attention is shifting earlier—toward detection instead of reaction. Toward tools that fit into existing care rather than complicate it. In this case, the funding is not about introducing something new into the system. It is about seeing what has long been missed—and doing so in time.